Thursday, April 10

MAIN CONFERENCE

7:30 am Registration, Morning Coffee, and One-to-One Meetings 

8:30 Chairperson’s Opening Remarks & Interactive Large Gr oup Discussion
Stuart Kliman, J.D., Head, Pharmaceuticals Practice Area, Vantage Partners

Alliance Management Interface

9:15 ‘Point-Counterpoint’: Where or in Which Function Does the Alliance Management Responsibility Reside?
Where and in which function the Alliance Management responsibility resides depends on organizational needs, size, culture, personnel, and a whole host of other considerations. We will debate the issues and pros/cons of alliance management residing in business development, in project management or being a stand-alone function. Those with one particular mindset will be provided a window of more options to consider, as well as more flexible perspectives in working with their alliance partners.
Mauri Okamoto-Kearney, Product Development & New Product Planning, KAI Pharmaceuticals, Inc. (Moderator)
Letizia Amadini Lane, Ph.D., Worldwide Business Development, Alliance Management, GlaxoSmithKline R&D
Andrew Eibling, Ph.D., Alliance Manager, Eli Lilly and Company
Ailsa Mendez, MBA, Director Project Governance, Functional Genetics
Kathleen Monroe, Director, Project Management, Dynavax Technologies
Julie Bukar, Acting Vice President, Project Management, Kalobios Pharmaceuticals

10:30 Networking Coffee Break and One-to-One Meetings 

11:00 Alliance Management and Project Management: A Successful Partnership
This session presents a case where a pharmaceutical company entered into an alliance with a small biotech to develop and commercialize a novel pharmaceuti-cal. The smaller firm, with the agreement of its larger partner, contracted a professional third-party project manager to lead the project and serve as a bridge be-tween the companies. This talk will describe how alliance management and project management worked together to facilitate communication, build trust and allay concerns.
Mary Jo Struttmann, MBA, Senior Director, Alliance Mgmt, Astellas US, LLC
Rick Boardman, Ph.D., Project Manager, Integrated Project Management Company, Inc.
Andy Myslicki, Manager, Project Planning & Execution, Integrated Project Management Company, Inc. (Moderator)

11:45 Alliance Management Interfaces – A Small Company Perspective
Alliance Managers in the Pharmaceutical Industry come from a wide variety of backgrounds and experiences. Some intended to become Alliance Managers; some found the opportunity there because of their current interactions and skill sets. Others still may have had the role thrust upon them, on top of their day job. This session will discuss the skill profile of an Alliance Manager and capability. Insights will be shared our building our own capability and from a significant number of partnerships we have with different sizes of companies.
Gavin Spencer, Ph.D., Licensing and Alliances Director, NICOX SA

12:15 pm How Does Business Development/Licensing Interface with Alliance Management?
Lilly’s framework for sourcing innovation is represented by its “find it - get it - create value” model. This model pairs the business development and alliance management functions early in the process, driving alignment discussions that benefit both functions, and more importantly the potential partner. This process will be reviewed and some examples will be discussed.
Michael Ransom, Manager, Alliance Management Operations, Eli Lilly Company 

12:45 Lunch On Your Own (Sponsorship Available) 

Alliance Governance: Contracting and Labeling

2:00 Alliance Governance: Strategic Recommendations for Contracting and Re-Negotiating Contracts
Good contracts are essential parts of all alliances, whether they are formal and detailed descriptions of responsibilities and rights, or informal ones providing a shared understanding of the alliance purpose and operation. A key element of a good contract is getting it right during the contracting phase of the relationship, before handing the alliance over to the Alliance Management function to manage and make successful. This presentation will explore the governance of business development/licensing interface with alliance management from the businessperson’s strategic perspective, not the lawyer’s perspective.
Harry Atkins, Senior Director, Alliance Management, Endo Pharmaceuticals, Inc. 

2:30 Pharmacovigilance and Labeling in Alliances
Pharmacovigilance and labeling responsibilities can be easily overlooked in alliances and in doing so can ultimately hurt the alliance. Parties need to understand the implications of ignoring pharmacovigilance and/or labeling in regards to Alliances. This talk will describe the role of pharmacovigilance and labeling in alliance agreements and provide examples of what can happen when pharmacovigilance and/or labeling are not addressed or addressed adequately in alliance agreements.
Vikki Hurley, Director Contractual Agreements, Pharmacovigilance, Wyeth 

3:00 Networking Refreshment Break and One-to-One Meetings 

Alliance Health Checks and Measuring Alliance Performance

3:15 How Do You Start an Alliance Management Team?
Alliance teams are central to the management of the joint corporate asset and their formation and management are one of the keys to success of the project objectives. All Team members must understand the key objectives for both companies entering the alliance and what competitive advantages and skill sets each partner brings. Two case studies will be presented that will describe the formation and performance measurement of alliance teams.
Ailsa Mendez, MBA, Director Project Governance, Functional Genetics
Katya Kovalskaia PMP, Associate Director, Product Development, Emergent BioSolutions

3:45 Failures and Success of Alliances: Two Case Studies on Why and Key Factors
Increasingly big pharma put more emphasis on not only to make a streamlined deal transaction, but also to be able to present to the other party a robust and successful Alliance Management. The reasons for failures in alliances are not technical, but rely more on cultural behaviors and lack of the proper focus as compared to the internal portfolio. AstraZeneca has had a longstanding interest to manage their alliances, and the speaker will present two cases on why the fail-ures and successes occurred, and how to mitigate the failures.
Lena Mårtensson, Director of Strategic Planning and Business Development Respiratory and Inflammation, AstraZeneca AB, Lund Sweden 

4:30 Interactive Breakout Discussions & Report Outs
Concurrent roundtables to discuss some of the more broad yet poignant questions facing the industry. Each roundtable will be limited to twelve (12) participants and a facilitator.

6:00 Networking Cocktail Reception and One-to-One Meetings 

7:00 Close of Day 

Pre Con  - Day 2